Institute of Physiology Czech Academy of Sciences, 142 20 Prague, Czech Republic.
Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN 55455, USA.
Neuropharmacology. 2018 May 1;133:129-144. doi: 10.1016/j.neuropharm.2018.01.027.
Xanomeline (3-(Hexyloxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole) is a muscarinic agonist that is considered to be functionally selective for the M/M receptor subtypes. Part of xanomeline binding is resistant to washing. Wash-resistant xanomeline activates muscarinic receptors persistently, except for the M subtype. Mutation of leucine 6.46 to isoleucine at M or M receptors abolished persistent activation by wash-resistant xanomeline. Reciprocal mutation of isoleucine 6.46 to leucine at the M receptor made it sensitive to activation by wash-resistant xanomeline. Lowering of membrane cholesterol made M and M mutants and M wild type receptors sensitive to activation by wash-resistant xanomeline. Molecular docking revealed a cholesterol binding site in the groove between transmembrane helices 6 and 7. Molecular dynamics showed that interaction of cholesterol with this binding site attenuates receptor activation. We hypothesize that differences in cholesterol binding to this site between muscarinic receptor subtypes may constitute the basis for xanomeline apparent functional selectivity and may have notable therapeutic implications. Differences in receptor-membrane interactions, rather than in agonist-receptor interactions, represent a novel possibility to achieve pharmacological selectivity. Our findings may be applicable to other G protein coupled receptors.
二甲磺酸加兰他敏(3-(己氧基)-4-(1-甲基-1,2,5,6-四氢吡啶-3-基)-1,2,5-噻二唑)是一种毒蕈碱激动剂,被认为对 M/M 受体亚型具有功能选择性。二甲磺酸加兰他敏的部分结合对洗涤具有抗性。洗去抗性的二甲磺酸加兰他敏持续激活毒蕈碱受体,但不包括 M 亚型。M 或 M 受体上亮氨酸 6.46 突变为异亮氨酸可消除洗去抗性的二甲磺酸加兰他敏的持续激活。M 受体上异亮氨酸 6.46 突变为亮氨酸使它对洗去抗性的二甲磺酸加兰他敏敏感。降低膜胆固醇使 M 和 M 突变体和 M 野生型受体对洗去抗性的二甲磺酸加兰他敏敏感。分子对接显示在跨膜螺旋 6 和 7 之间的凹槽中有一个胆固醇结合位点。分子动力学显示胆固醇与该结合位点的相互作用减弱了受体的激活。我们假设毒蕈碱受体亚型之间该位点与胆固醇结合的差异可能构成二甲磺酸加兰他敏明显功能选择性的基础,并可能具有显著的治疗意义。受体-膜相互作用的差异,而不是激动剂-受体相互作用的差异,代表了实现药理学选择性的一种新可能性。我们的发现可能适用于其他 G 蛋白偶联受体。